Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethylammonium SCHEMBL27993313 | 1.00 | PTGS1 (0.36) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL1226065 | 1.00 | PTGS1 (0.36) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL1377988 | 0.97 | PTGS1 (0.37) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL1377985 | 0.97 | PTGS1 (0.37) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL141480 | 0.94 | PTGS1 (0.36) | PTGS1AKR1C3FFAR3LCKFYN | |
| Trimethylammonium SCHEMBL141479 | 0.94 | PTGS1 (0.36) | PTGS1AKR1C3FFAR3LCKFYN | |
| Bromide SCHEMBL27583888 | 0.91 | — | — | |
| SCHEMBL133954 | 0.87 | — | — | |
| SCHEMBL15042 | 0.87 | — | — | |
| SCHEMBL1396002 | 0.87 | FFAR3 (0.43) | PTGS1AKR1C3FFAR3LCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 498 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140234225-A1 | METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-08-21 | — | — | US | claimed |
| US-8652464-B2 | Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer | ALKERMES PHARMA IRELAND LIMITED (IE) | 2014-02-18 | — | — | US | claimed |
| US-20130251805-A1 | LOW VISCOSITY LIQUID DOSAGE FORMS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-09-26 | — | — | US | claimed |
| US-20130224123-A1 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | ALKERMES PHARMA IRELAND LIMITED (IE) | 2013-08-29 | — | — | US | claimed |
| US-8323641-B2 | Nanoparticulate compositions having lysozyme as a surface stabilizer | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-12-04 | — | — | US | claimed |
| US-20120121653-A1 | Novel mometasone compositions and methods of making and using the same | ELAN PHARMA INTERNATIONAL LIMITED | 2012-05-17 | — | — | US | claimed |
| JP-4838514-B2 | — | — | 2011-12-14 | — | — | JP | claimed |
| EP-2353590-A1 | Aerosol and injectable formulations of nanoparticulate benzodiazepine | Elan Pharma International Limited (IE) | 2011-08-10 | — | — | EP | claimed |
| EP-2332524-A1 | Aerosol and injectable formulations of nanoparticulate benzodiazepine | Elan Pharma International Limited (IE) | 2011-06-15 | — | — | EP | claimed |
| EP-2263651-A2 | Low viscosity liquid dosage forms | Elan Pharma International Limited (IE) | 2010-12-22 | — | — | EP | claimed |
| EP-1587499-A1 | NANOPARTICULATE TOPIRAMATE FORMULATIONS | Elan Pharma International Limited (IE) | 2005-10-26 | — | — | EP | claimed |
| US-20040258758-A1 | Nanoparticulate topiramate formulations | ELAN PHARMA INTERNATIONAL, LTD. | 2004-12-23 | — | — | US | claimed |
| EP-1471887-A2 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | Elan Pharma International Limited (IE) | 2004-11-03 | — | — | EP | claimed |
| US-20040208833-A1 | Novel fluticasone formulations | ELAN PHARMA INTERNATIONAL LTD. | 2004-10-21 | — | — | US | claimed |
| WO-2004078162-A1 | NANOPARTICULATE TOPIRAMATE FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-09-16 | — | — | WO | claimed |
| US-20040164194-A1 | System and method for milling materials | ELAN PHARMA INTERNATIONAL LIMITED | 2004-08-26 | — | — | US | claimed |
| WO-2004069225-A1 | NOVEL FLUTICASONE FORMULATIONS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-08-19 | — | — | WO | claimed |
| WO-2004050059-A1 | LOW VISCOSITY LIQUID DOSAGE FORMS | ELAN PHARMA INTERNATIONAL LTD. (IE) | 2004-06-17 | — | — | WO | claimed |
| US-20040105889-A1 | Low viscosity liquid dosage forms | ELAN PHARMA INTERNATIONAL LIMITED | 2004-06-03 | — | — | US | claimed |
| WO-2003066021-A2 | DRUG NANOPARTICLES WITH LYSOZYME SURFACE STABILISER | ELAN PHARMA INTERNATIONAL, LTD. (IE) | 2003-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258758-A1 | Nanoparticulate topiramate formulations | FAH, MTHFD1, DHODH | PTGS1 1237/4885AKR1C3 755/4885FFAR3 584/4885 |
| US-20140234225-A1 | METHOD OF TREATMENT USING NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | LPO, LCT, LIPA | PTGS1 3132/4885AKR1C3 1240/4885FFAR3 2977/4885 |
| US-20130224123-A1 | NANOPARTICULATE COMPOSITIONS HAVING LYSOZYME AS A SURFACE STABILIZER | LPO, LCT, CTSA | PTGS1 3084/4885AKR1C3 1533/4885FFAR3 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.